Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gervois

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Frontiers in Immunology|August 6, 2019
The Emerging Role of Triggering Receptor Expressed on Myeloid Cells 2 as a Target for Immunomodulation in Ischemic StrokePascal Gervois, Ivo Lambrichts
Revue D'Epidemiologie Et De Sante Publique|September 23, 1977
[Atmospheric pollution and acute respiratory diseases. Denain and Quievrechain epidemiological study (author's transl)]M Gervois, G Dubois, S Gervois, et al.
Expert Opinion on Therapeutic Targets|August 29, 2012
PPARα as a therapeutic target in inflammation-associated diseasesPhilippe Gervois, Roxane M Mansouri
Targeted Oncology|February 22, 2012
Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?F Jotereau, N Gervois, N Labarrière
Current Opinion in Lipidology|May 18, 1999
Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and agingI Pineda Torra, P Gervois, B Staels
Nature Clinical Practice. Endocrinology & Metabolism|January 24, 2007
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptorsPhilippe Gervois, Jean-Charles Fruchart, Bart Staels
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|November 5, 2004
Random cuts in binary mixtures of spheresAnnie Gervois, Luc Oger, Jean-Paul Troadec
International Journal of Clinical Practice. Supplement|July 23, 2005
Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonistsP Gervois, J C Fruchart, B Staels
Human Immunology|June 1, 1990
High proliferative capacity and specific antiautologous melanoma cytotoxicity of a human T-lymphocyte clone derived from tumor-infiltrating lymphocytesN Gervois, F Heuze, E Diez, et al.
The Journal of Experimental Medicine|May 1, 1996
Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactionsN Gervois, Y Guilloux, E Diez, et al.
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Frontiers in Immunology|August 6, 2019
The Emerging Role of Triggering Receptor Expressed on Myeloid Cells 2 as a Target for Immunomodulation in Ischemic StrokePascal Gervois, Ivo Lambrichts
Revue D'Epidemiologie Et De Sante Publique|September 23, 1977
[Atmospheric pollution and acute respiratory diseases. Denain and Quievrechain epidemiological study (author's transl)]M Gervois, G Dubois, S Gervois, et al.
Expert Opinion on Therapeutic Targets|August 29, 2012
PPARα as a therapeutic target in inflammation-associated diseasesPhilippe Gervois, Roxane M Mansouri
Targeted Oncology|February 22, 2012
Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?F Jotereau, N Gervois, N Labarrière
Current Opinion in Lipidology|May 18, 1999
Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and agingI Pineda Torra, P Gervois, B Staels
Nature Clinical Practice. Endocrinology & Metabolism|January 24, 2007
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptorsPhilippe Gervois, Jean-Charles Fruchart, Bart Staels
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|November 5, 2004
Random cuts in binary mixtures of spheresAnnie Gervois, Luc Oger, Jean-Paul Troadec
International Journal of Clinical Practice. Supplement|July 23, 2005
Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonistsP Gervois, J C Fruchart, B Staels
Human Immunology|June 1, 1990
High proliferative capacity and specific antiautologous melanoma cytotoxicity of a human T-lymphocyte clone derived from tumor-infiltrating lymphocytesN Gervois, F Heuze, E Diez, et al.
The Journal of Experimental Medicine|May 1, 1996
Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactionsN Gervois, Y Guilloux, E Diez, et al.
Pageof 13